Anteris Technologies To Present First 30-Day Clinical And Hemodynamic Outcomes For Its Medium-Size DurAVR Transcatheter Heart Valve At The Transcatheter Cardiovascular Therapeutics Conference, October 31-November 3
The presentation will report 30-day outcomes in patients with severe aortic stenosis who received the medium-size DurAVR THV in the ongoing EMBARK study. Since 2021 over 130 patients have been treated with the DurAVR
Anteris is showing early results from its heart valve device. When a company shares positive patient data, it hints the product might work well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.